For Physicians

For Immediate Release Contact: Lesia Golden OHC Marketing Department 513-751-2273 ext. 10204 lesia.golden@usoncology.com Cincinnati, Aug. 9, 2017 — OHC, the region’s premier source of treatment for nearly every form of cancer and complex blood   (Read More)

Multiple Myeloma, a rare cancer of the plasma cells, has 30,300 new cases diagnosed each year. With more than 12,650 deaths annually, a quick review is timely: Causes Although exact causes remain unknown, scientists have made progress in   (Read More)

OHC’s Research Department’s complex clinical trial menu provides an opportunity for patients in and around the Tri-State to participate in innovative studies which include targeted and immunotherapies. In order to obtain FDA approval, all drugs   (Read More)

Bladder cancer – the fourth most common cancer in the United States among men and ninth among women – arises in the lining of the bladder and is highly treatable. With 50,000 new cases diagnosed each year, a quick review is timely: Risk Factors   (Read More)

Although melanoma accounts for only 1 percent of all skin cancers, the American Cancer Society estimates that about 76,380 new melanomas will be diagnosed in 2016, and more than 10,000 persons will die of the disease. As you know, skin cancer is the   (Read More)

The OHC Research Department’s complex clinical trial menu provides an opportunity for patients in and around the Tri-state to participate in innovative studies which include targeted therapies. OHC’s history of successful participation in   (Read More)

The OHC Department of Clinical Research is offering a clinical trial, GYN41, utilizing Doxil with or without Trabectedin (YONDELIS), a DNA-binding agent that inhibits inducible transcription. This trial is enrolling advanced relapsed patients with   (Read More)

According to the American Cancer Society’s estimates for cervical cancer in the United States for 2016: About 12,990 new cases of invasive cervical cancer will be diagnosed. About 4,120 women will die from cervical cancer. Historically,   (Read More)

OHC is offering two new clinical trials. To view our entire research clinical trial menu, please click here. 1) Lynch Syndrome Trial This is an investigational trial that runs analyses on patients’ blood, saliva, and tumor tissue to determine if   (Read More)

We have seen significant progress in how cancer is treated this last year. Individualized and personalized therapy has revolutionized the treatment plan for many cancer types. Nivolumab, a new immunotherapy drug used to treat advanced non-squamous,   (Read More)

OHC recently received accreditation as an Oncology Medical Home from the Commission on Cancer (CoC). This recognition distinguishes OHC as one of the nation’s premier independent cancer practices as the accreditation was awarded to only nine   (Read More)

Radio, television, publications, even YouTube, are all talking about clinical research and the significant breakthroughs that have surfaced in the treatment of cancer over the last couple of years. Cincinnati community physicians, their patients, and   (Read More)

There is a causal-relationship between gastroesophageal reflux disease (GERD), Barrett’s esophagus, and laryngeal cancer. GERD is a condition marked by the reflux of stomach contents that causes troublesome symptoms and/or complications. Chronic   (Read More)

Lymphomas, blood cell tumors that usually originate in lymphatic tissues (and can spread to other organs), are among the most diverse and most curable of all malignancies. There are two major groups of lymphomas: About 90 percent are non-Hodgkin   (Read More)

The OHC Research Department’s robust clinical trial menu provides an opportunity for patients in and around the Tri-state to participate in innovative studies which include targeted therapies. OHC’s history of successful participation in   (Read More)